HOME >> MEDICINE >> NEWS
Preparing for European market launch

Ventracor Limited (ASX: VCR) today announced the first patient has been implanted with the VentrAssist in a new study designed to build on clinical momentum from the CE Mark Trial and prepare for European market launch.

The BRACE study (Baseline Results And Cost Effectiveness) will add to the body of evidence for the performance of the VentrAssist left ventricular assist device (LVAD) in up to 10 new centres in Europe. The new centres are in addition to the current Australian, NZ and European sites.

The BRACE study is a key component of Ventracor's commercialisation strategy to rapidly grow revenues after the anticipated CE Mark approval in early 2007.

The cost effectiveness results of the BRACE study will also be used to help obtain or increase reimbursement in key European markets.

After approval by the Regional Hospital Ethics Committee in Oslo, Norway, the first patient in the BRACE study, a 16 year-old girl was implanted last week.

Principal Investigator Dr Arnt Fiane at Rikshopitalet - Radiumhospitalet Medical Centre said: "We are excited about participating in the BRACE study for this potentially world-leading life-saving technology." Dr. Fiane added the patient was making a satisfactory recovery.

Ventracor Limited Chief Operating Officer Peter Crosby said: "We are very conscious that regulatory approval does not immediately equate to market acceptance.

"The BRACE study builds on the CE Mark Trial to expand clinical knowledge and understanding of the VentrAssist."

"By the time the VentrAssist receives CE mark approval later this year, we expect to have many more centres implanting the VentrAssist under the BRACE protocol and we can rapidly move to grow revenues from this established customer base.

"There have now been more VentrAssist third generation (3G) centrifugal LVADs implanted than all third generation centrifugal pumps from all our competitors combined," Mr Crosby said.


'"/>

Contact: Andrew Geddes
61-29-406-3086
Research Australia
19-Jun-2006


Page: 1

Related medicine news :

1. Preparing for an influenza pandemic: A triage protocol in the face of limited resources
2. Rutgers College of Nursing to host Preparing for Natural Disasters Forum November 3
3. Preparing our medical frontline for the future
4. Look to the future: Preparing for baby boomer dementia epidemic
5. European heat waves double in length since 1880
6. European Space Agencys Envisat captures breath of volcano
7. Polish journalist scoops first prize in prestigious European award
8. UK and other European countries should introduce universal childhood hepatitis B vaccination
9. Elsevier partners with European Federation of Organizations for Medical Physics
10. Asia-European collaboration addresses water management in Indonesia
11. Leading European experts in magnetic resonance for animals

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... Compliance and Safety for the President’s Malaria Initiative (PMI) Africa Indoor Residual ... Innovation to Action Award. , The Innovation to Action Award, a USAID ...
(Date:9/19/2017)... ... 2017 , ... MelaKids, a Laredo-based company, has introduced a new concept for ... Nature gives us a full supply of melanin – in the back of the ... glare-reducing pigment; however, around the age of thirty, we develop a yellow-brown pigment in ...
(Date:9/19/2017)... ... 19, 2017 , ... The Workgroup for Electronic Data Interchange (WEDI) , ... in healthcare information exchange and a trusted advisor to the U.S. Department of Health ... entitled Barriers to Adoption of the ERA and EFT Transactions . , ...
(Date:9/19/2017)... ... ... Public outrage over the toxins that exist in tap water and the ... industry itself to research, develop and ultimately supply consumers with healthy drinking water alternatives. ... natural alkaline water technologies, water filtration systems, and consumer education. ...
(Date:9/19/2017)... , ... September 19, 2017 , ... ... TX, announces the launch of its magnesium-based orthopedic medical device, OsteoCrete®. OsteoCrete® bone ... the first in the U.S. to incorporate magnesium, a critical property for bone ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)...  Medical professionals are expected to continuously ... their patients. Medical simulations offer clinicians the ... Simulation provides a safe method for teaching ... refine techniques and build confidence, without putting ... such as augmented reality, will now provide ...
(Date:9/6/2017)... Sept. 6, 2017 NeuroRx, a clinical stage biopharma ... and Behavior (ASIB), has been granted Fast Track status by ... of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). ... trial of this sequential therapy targeting patients who are admitted ... ...
(Date:9/5/2017)... Colo. , Sept. 5, 2017 Sapheneia ... XR-29 DoseCheck solution. Scannerside DoseCheck is a third-party Vendor ... existing CT scanners and allows compliance with current MITA ... Sapheneia-Scannerside proprietary XR 29 DoseCheck solution is specifically designed ... and alerts of potential radiation doses over a predefined ...
Breaking Medicine Technology:
Cached News: